# OnCo record paper-himalaya-nejm-evidence-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-himalaya-nejm-evidence-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-himalaya-nejm-evidence-2022" ;
  schema:name "HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma"@en ;
  schema:description "A single priming dose of the CTLA-4 antibody tremelimumab followed by durvalumab lengthened survival compared with sorafenib in advanced liver cancer without the bleeding risk of bevacizumab, giving a second first-line immunotherapy standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-himalaya-nejm-evidence-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/EVIDoa2100070>, <https://pubmed.ncbi.nlm.nih.gov/38319892/> ;
  schema:sameAs <https://doi.org/10.1056/EVIDoa2100070> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Abou-Alfa GK, Lau G, Kudo M, et al." ;
  onco:cancers <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/> ;
  onco:trials <https://onco.cc/trials/himalaya/> ;
  onco:journals <https://onco.cc/journals/nejm-evidence/> .